MedPath

Study of antibiotic-resistant lactic acid bacteria cobination eradication therapy for H. pylori infectio

Phase 3
Conditions
Helicobacter pylori infection
Registration Number
JPRN-jRCTs051180155
Lead Sponsor
Inoue Jun
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
76
Inclusion Criteria

(1) Patient who was suspected for H. pylori infection and were positive for H. pylori in one of the following examination, urea breath test, H. pylori stool antigen test, H.pylori antibody test in the urine or in the blood, rapid urease test.
(2) Patient who is expected an beneficial effect after H.pylori radication treatment.
(3) Patients written consent from the person is obtained.
(4) Patients without allergy to the use drugs.

Exclusion Criteria

(1) Patients who have already taken H. pylori eradication therapy before.
(2) Patients who had taken any antibiotics or PPI within 4 weeks before the start day of the study.
(3) Patients under 20 years.
(4) Patients who had taken gastric cancer sugery before (except endoscopic surgery).
(5) Patients with severe renal impairment, serious heart disease, or severe liver disease.
(6) Patients with allergy to the use drugs.
(7) In the cases the test doctor has determined the patient does not fit the study.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The occurrence of diarrea during H. pylori eradication therapy (day 0 to day 6) in biofermin R administration group and placebo group.
Secondary Outcome Measures
NameTimeMethod
1.Gut microflora change (alpha and beta divesity change) at day7, day 14 and pont of judgement after eradication therapy <br>2.Occurrence of side effect other than diarrhea <br>3.FSSG scal score before and after therapy <br>4.Serum diamine oxydase activity before and after therapy <br>5.Occurence of diarrhea after eradication therapy (between day 7 to day 13)<br>6.Number of defecations during and 7 days after antibiotic treatment. <br>7.Percentage of stool properties in the Bristol Stool Form Scores during and 7 days after antibiotic treatment.<br>A stratified analysis will be performed on the primary endpoint and secondary endpoints based on background items (age, gender, etc) to examine the influence of patient background.
© Copyright 2025. All Rights Reserved by MedPath